Global Erectile Dysfunction Drugs Market – Industry Analysis and Forecast (2022-2029)

Global Erectile Dysfunction Drugs Market is expected to grow at a CAGR of 3.4% during the forecast period. Global Erectile Dysfunction Drugs Market is expected to reach US$ 2.56 Bn. by 2029.

Although other types of medical treatments for erectile dysfunction (e.g. intracavernosal injections, intraurethral suppositories) have been available for many years, their use has been associated with specific adverse events (e.g. local pain, priapism, fibrosis) and low compliance rates due to the invasive nature of these therapies. Alprostadil, papaverine, and organic nitrates are examples of topical treatments that have been approved by medical bodies as alternate possibilities due to their less intrusive routes of delivery. Hormonal treatments, vacuum constriction devices, and surgical therapies are further second-line therapeutic options for people with persistent ED or who cannot take PDE-5 medication (e.g. penile prosthesis implants, penile arterial bypass).

Globally, erectile dysfunction (ED) has become increasingly common, even among young individuals, and is a growing health problem that has a substantial impact on men's quality of life. The number of ED cases globally is expected to reach nearly 322 million by the end of 2025. Erectile dysfunction drugs (EDMs) are increasingly being used as a sexual enhancement aid among men who do not have a medical justification, as per overwhelming evidence. Recreational EDM usage has been linked to increased sexual risk behaviors, a higher risk of STIs, including HIV infection, and a high prevalence of simultaneous illegal substance consumption. The Food and Drug Administration (FDA) now approves three oral drugs for the treatment of erectile dysfunction (ED): sildenafil (Viagra), tadalafil (Cialis), and vardenafil (Levitra). These erectile dysfunction drugs are widely accepted and effective for treating ED of diverse etiologies, and it is estimated that sildenafil alone has been prescribed to over 25 million men globally.

The Erectile Dysfunction Drugs Market is segmented based on Product, End-user, and Region. The growth of various segments helps the report users in acquiring knowledge of the many growth factors expected to be prevalent throughout the market and develop different strategies to help identify core application areas and the gap in the target market. The report provides an in-depth analysis of the market and contains meaningful insights, facts, historical data, and statistically supported and industry-validated market statistics. It also includes estimates based on an appropriate set of assumptions and methodologies.



To know about the Research Methodology :- Request Free Sample Report

The objective of the report is to present a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, industry-validated market data and projections with a suitable set of assumptions and methodology. The report also helps in understanding global erectile dysfunction drugs market dynamics, structure by identifying and analysing the market segments and project the global market size. Further, the report also focuses on the competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence. The report also provides PEST analysis, PORTER’s analysis, and SWOT analysis to address questions of shareholders to prioritizing the efforts and investment in the near future to the emerging segment in the global erectile dysfunction drugs market.

The report study has analyzed revenue impact of covid-19 pandemic on the sales revenue of market leaders, market followers and disrupters in the report and same is reflected in our analysis.

Growing elderly population and high rate of chronic diseases such as kidney failure, hormonal imbalance, diabetes, hypertension, and neurological disorders are increasing demand for erectile dysfunction drugs globally. Additionally, increasing awareness among patients about erectile dysfunction and availability of treatment are contributing significantly towards the growth of erectile dysfunction drugs market. Then, even with of increasing demand for erectile dysfunction drugs, the global market is facing decline owing to patent expiry of market blockbuster drugs such as Viagra etc.

The key factors that are helping the growth of global erectile dysfunction drugs market include a rise in the competition among the major market players, increasing number of men suffering from erectile dysfunction, and a number of drugs available in the market. Though, some factors that can harm the market growth contain the availability of counterfeit drugs, the increasing manufactures of generic drugs in the market, and patent expiry of a number of blockbuster drugs.

Viagra accounted for over 45% of the total revenue in 2021. It is mostly considered as the first line of treatment for erectile dysfunction. Brand loyalty and benefits associated with this drug such as high efficacy and effectiveness are the major factors attributing for its large market share.

Pharmaceutical companies segment is expected to dominate the global erectile dysfunction drug market during the forecast period. Easy availability of erectile dysfunction drugs at pharmaceutical companies, low price of the drugs, and expansion of leading retail pharmacy chains across the globe drive the segment. The hospital pharmacies segment held the second largest share of the global erectile dysfunction drugs market.

Region-wise, North America dominated the global erectile dysfunction drugs market in 2021 followed by Europe. This growth in the market is attributable to the high awareness and the increasing research and development activities. Moreover, factors such as the presence of favourable medical reimbursement policies, the high prevalence of erectile dysfunction, and a growing geriatric population are fuelling the growth of dysfunction drugs market presence in North America.
Global Erectile Dysfunction Drugs Market Scope: Inquire before buying



Erectile Dysfunction Drugs Market


Report Coverage
Details


Base Year:
2021
Forecast Period:
2022-2029


Historical Data:
2017 to 2022
Market Size in 2021:
US $ 5 Bn.


Forecast Period 2022 to 2029 CAGR:
4.5%
Market Size in 2029:
US $ 1.96 Bn.


 Segments Covered:
by Product
• Viagra
• Cialis
• Levitra
• Stendra
• Zydena


by End-user
• Pharmaceutical Companies
• Hospitals
• Clinics
• Others


by Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies



Global Erectile Dysfunction Drugs Market, by Region
• North America
• Europe
• Asia Pacific
• Middle East and Africa
• South America
Global Erectile Dysfunction Drugs Market Key Players
• Apricus Biosciences
• Bayer AG
• Cristália,
• Eli Lilly and Company, Inc.
• Pfizer, Inc.
• Dong-A-Pharmaceutical Co., Ltd.
• S.K. Chemicals Co., Ltd.
• Vivus, Inc.
• Teva Pharmaceutical Industries Ltd.
• Meda Pharmaceuticals, Inc.
• Ferring Pharmaceuticals
• GlaxoSmithKline PLC
• Metuchen Pharmaceuticals LLC
• Boston Scientific
• Coloplast
• Viatris
• Produtos Quimicos Farmaceuticos Ltd.

Frequently Asked Questions:

1. Which region has the largest share in Global Erectile Dysfunction Drugs Market?
Ans: North America region held the highest share in 2021.

2. What is the growth rate of Global Erectile Dysfunction Drugs Market?
Ans: The Global Erectile Dysfunction Drugs Market is growing at a CAGR of 3.4% during forecasting period 2022-2029.

3. What is scope of the Global Erectile Dysfunction Drugs market report?
Ans: Global Erectile Dysfunction Drugs Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period.

4. Who are the key players in Global Erectile Dysfunction Drugs market?
Ans: The important key players in the Global Erectile Dysfunction Drugs Market are – Apricus Biosciences, Bayer AG, Cristália,, Eli Lilly and Company, Inc., Pfizer, Inc., Dong-A-Pharmaceutical Co., Ltd., S.K. Chemicals Co., Ltd., Vivus, Inc., Teva Pharmaceutical Industries Ltd., Meda Pharmaceuticals, Inc., Ferring Pharmaceuticals, GlaxoSmithKline PLC, Metuchen Pharmaceuticals LLC, Boston Scientific, Coloplast, Viatris, and Produtos Quimicos Farmaceuticos Ltd.

5. What is the study period of this market?
Ans: The Global Erectile Dysfunction Drugs Market is studied from 2021 to 2029.